Last reviewed · How we verify
travoprost, latanoprost, or bimatoprost
These prostaglandin F (FP) receptor agonists increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
These prostaglandin F (FP) receptor agonists increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | travoprost, latanoprost, or bimatoprost |
|---|---|
| Sponsor | Robin, Alan L., M.D. |
| Drug class | Prostaglandin F receptor agonist |
| Target | FP prostaglandin receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost, latanoprost, and bimatoprost are all prostaglandin analogs that bind to the FP prostaglandin receptor on the ciliary muscle and trabecular meshwork. By activating this receptor, they enhance drainage of aqueous humor through the uveoscleral (unconventional) pathway, leading to decreased intraocular pressure. This mechanism makes them effective for treating glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation
- Conjunctival hyperemia
- Eyelash growth (hypertrichosis)
- Eye irritation or discomfort
- Periocular skin darkening
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- PSLT Compared to Prostaglandin Analogue Eye Drops (NA)
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (PHASE4)
- Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
- Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy (PHASE4)
- Efficacy of Changing to TRAVATAN® From Prior Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- travoprost, latanoprost, or bimatoprost CI brief — competitive landscape report
- travoprost, latanoprost, or bimatoprost updates RSS · CI watch RSS
- Robin, Alan L., M.D. portfolio CI